直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • 生命科学
    • Transportation and Logistics
  • 经验

尽职调查、许可和意见

About

严谨的商业决策,如投资新产品或新公司、推出新品牌、收购知识产权资产或建立合作伙伴关系,都需要仔细调查和分析。知识产权尽职调查在决定是否继续进行交易及其最终估值和结构方面发挥着重要作用。在这类关键问题上,技术专长和实务经验是无可替代的。飞翰深知,调查工作必须快速、高效地进行,我们的团队经验丰富,随时能以各种技术协助客户及时、经济高效地开展尽职调查和法律意见项目,并能灵活地适应任何特殊情况。我们帮助客户评估竞争格局,并提供可靠的意见,以确认不侵权或提出论据,为实现商业目标扫清障碍。我们还考虑与知识产权相关的潜在影响领域,如贸易和出口管制或隐私问题。通过数十年与成熟行业和新兴行业客户的密切合作,我们知道问题所在及关注重点,从而满足客户需求。

达成商业目标所需的服务与指导

经验丰富的律师对于管理知识产权资产同样重要。飞翰是率先开发知识产权组合管理和运营等全方位业务服务的律师事务所之一。我们分析专利组合,以便发现机遇;我们通过增补申请和收购专利,提高专利组合的价值;我们发掘商业机会、为创收布局;而后通过出售或许可专利实现创收计划。多年来我们根据的客户知识产权情况帮助他们做出商业决定,并从经验中提取出最佳的实践方式。很多创新型初创企业、跨国公司和其它以知识产权为驱动力的组织在知识产权业务上,选择飞翰为其提供专业指导。

我们帮助客户查明并确定资产的优先级,以确保商业计划围绕强大知识产权组合。我们会推荐许可技术或出售边际资产来获得收益,捐赠甚至放弃资产以降低成本,且通过找出收购目标以加强或扩展现有的组合。我们帮助客户建立和运行许可计划,从而产生可观的收入来源。交易可以是简单的收入许可,也可以是复杂的战略联盟,为双方提供产品和市场准入。我们为专利计划的各个方面提供专业建议,从最初的秘密评估到管理知识产权协议的专利组合。无论是收购还是转让权利,我们都会在会议室和谈判桌上与客户携手应对。

合作提升知识产权和品牌价值

保护和促进创新及市场信任是飞翰的基本宗旨。飞翰坚持具有服务精神的文化且保持在专业律师协会、法律协会和贸易协会的领导地位,并与工业界同仁和政府合作以促进知识产权保护和提高行业专业水准。我们参与的组织包括美国知识产权法协会(AIPLA)、美国律师协会、知识产权专家协会(VPP)、英国特许专利律师协会(CIPA)、欧洲专利协会(EPI)、国际知识产权律师联合会(FICPI)、德国知识产权和版权联合会(GRUR)、欧洲专利局专利代理人协会(epi)、知识产权所有者协会(IPO)、国际保护知识产权协会(AIPPI)、国际许可贸易工作者协会(LESI)、中国分会(LESI China)、美国和加拿大分会(LES)。

Everyone in this practice

业务范围

尽职调查

在瞬息万变、来势汹汹的并购、合作和投资交易中,得到准确、全面的知识产权评估至关重要。

View 尽职调查

出口管制

The reach of trade and export requirements is broad, affecting U.S. companies or organizations that export materials, software, and technologies, as well as non-U.S. companies that may utilize such exports in products of their own.

View 出口管制

自由运作意见

A Freedom to Operate (FTO) opinion helps limit the risk of future litigation and avoid unnecessary expense related to a new product or acquisition.

View 自由运作意见

许可、专利池、及其它交易

专利、商业秘密或部分知识产权组合通常可以用来产生收入流、开拓新市场或打击竞争对手。

View 许可、专利池、及其它交易

意见及咨询

我们为客户解决专利有效性、可执行性、滥用、回避设计、许可潜力、知识产权合同构建和执行、以及出口管制等问题。

View 意见及咨询

专利挖掘及布局

在大环境下了解企业自身知识产权资产能够使企业更清楚自己在市场上的地位,识别周遭潜在的威胁及需要避让的障碍,发现空白领域,找到自信向前迈进的机会。

View 专利挖掘及布局

隐私

From data gathering to data storage, from privacy by design to governance and legal compliance, all industries and sectors are faced with complex and often unsettled issues related to privacy.

View 隐私

标准必要专利 (SEP)

标准必要专利 (SEP) 是指被纳入某种技术标准的发明。处理 SEP 诉讼和许可谈判需要特殊的经验。

View 标准必要专利 (SEP)

经验

Advised a consumer-focused private investment firm on healthcare regulatory aspects of its definitive agreement to acquire a majority stake in a skin barrier and skin health brand*

Advised a consumer-focused private investment firm on healthcare regulatory aspects of its definitive agreement to acquire a majority stake in a skin barrier and skin health brand.

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products*

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias*

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers*

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company*

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.

Regeneron Pharmaceuticals Inc v. Kymab Ltd.*

Represented Regeneron against Kymab on patents covering a transgenic mouse platform for antibody discovery in its appeal.

[2020] UKSC 27, Appeal number: UKSC 2018/0131, Supreme Court of the United Kingdom

More

专业见解

Conference

IAM Live: SEP Summit Global 2026

September 9-10, 2026

London

Webinar

FRAND Rate Setting and Negotiation Conduct: U.S., UK, EU, and China

August 13, 2026

Webinar

Articles

Privacy Law Mid-Year Update: Key EU and UK Data Protection Decisions

August 13, 2026

Articles

Blaker v. NetScout Systems: A Narrow Reading of the Pen Register and Trap and Trace Provisions of the California Invasion of Privacy Act in California State Court

July 29, 2026

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Articles

When the Classroom Goes Dark: Lessons from the Canvas Breach for Corporate Cyber Preparedness

July 8, 2026

More

近期活动

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

Conference

2026 FCBA Global Series Fall Session

October 14-16, 2026

Dublin

Conference

2026 IPO Annual Meeting

September 27-29, 2026

Toronto

Conference

IAM Live: SEP Summit Global 2026

September 9-10, 2026

London

新闻

Commentary

Why Global IP Litigants Keep Turning to English Courts

August 19, 2026

Award/Ranking

Fourteen Finnegan Attorneys Named to the 2026 IAM Strategy 300 List

August 13, 2026

Award/Ranking

Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers

June 22, 2026

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP